% | $
Quotes you view appear here for quick access.

Vertex Pharmaceuticals Incorporated Message Board

  • isaac_dji isaac_dji Jan 9, 2006 7:43 AM Flag

    5.5 LOG10 HCV Reduction is UNPREDENTED

    The 5.5 log10 REDUCTION in HCV levels, achieved with VX-950 and PEG-IFN, in 14 days, is the BEST BY FAR. Moreover, this was achieved in genotype 1 hepc patients -- the most difficult HCV genotype to treat effectively (and the most common in the US). In addition, in 50% of the patients, the HCV RNA could no longer be detected (below detection limit).


    "VX-950, an investigational oral hepatitis C virus (HCV) protease inhibitor, dosed in combination with pegylated interferon alfa-2a (Pegasys�; peg-IFN), achieved a rapid and dramatic reduction in plasma viral RNA levels in patients with chronic genotype 1 HCV infection. In this Phase Ib study, the combination of VX-950 and peg-IFN produced an initial median reduction in plasma HCV RNA of more than 3 log10 in the first two days, followed by continued decline to a median 5.5 log10 reduction in HCV RNA at day 14, which equates to a 300,000- fold reduction in viral levels. The majority of patients (6 of 8) receiving the combination achieved HCV RNA levels below the limit of quantitation (30 IU/mL, as measured by the Roche TaqMan� assay) at 14 days, with 4 of 8 patients achieving HCV RNA levels below the limit of detection (10 IU/mL, Roche TaqMan�). The antiviral activity of the combination through 14 days was significantly greater than the activity of VX-950 administered as a single agent, and much greater than peg-IFN alone. In addition, VX-950 appeared to be well-tolerated when dosed alone and in combination with peg-IFN in the study. " (see link below)

    Folks, the REAL ERA of VX-950 (and VRTX) has begun.

    It will all be history soon.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
83.675+0.235(+0.28%)10:49 AMEDT